Treatment Details – 26.8 months
|Patients: This phase II study involved 20 patients with pleural mesothelioma. The majority (75%) were male. Their median age was 67.5, ranging from 46 to 79 years of age.|
Treatment: Patients were treated with the chemotherapy drugs pemetrexed and gemcitabine.
Toxicity: One patient died from multiple organ failure related to treatment with the study drugs. The most frequently reported grade 3 and 4 toxicities were neutropenia (occurring in 60% of patients), febrile neutropenia (reported in 10% of patients), and anemia (reported in 1 patient). Other grade 3 and 4 toxicities were fatigue, dehydration, constipation, vomiting, diarrhea, dyspnea, and nausea.
Results: The median overall survival was 26.8 months.
Support: This study was supported by research funds from Eli Lilly & Co., which markets gemcitabine as GemzarÒ and pemetrexed as AlimtaÒ.
Correspondence: Dr. George R. Simon